during the promptly evolving subject of oncology analysis, accurate and effective mutation screening is vital for developing targeted therapies. The KRAS providers Platform plays a pivotal job Within this landscape by providing extensive options for KRAS mutation profiling and Assessment. KRAS mutations, located in close to ninety five% of RAS-conn